Showing 4481-4490 of 9153 results for "".
- Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Islandhttps://practicaldermatology.com/news/dr-mario-e-lacouture-named-new-chief-of-dermatology-at-nyu-langone-hospital-long-island/2462164/Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island. Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medic
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- Zeroing in on What Causes Melanoma to Spread to the Brainhttps://practicaldermatology.com/news/zeroing-in-on-what-causes-melanoma-to-spread-to-the-brain/2462160/More than half of patients with advanced melanoma will see the disease spread to the brain, where it rapidly progresses, often leading to death in only three to four months. Researchers in Moffitt Cancer Center’s
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi
- FDA Grants Priority Review for Abeona's Pz-cel BLAhttps://practicaldermatology.com/news/fda-grants-priority-review-for-abeonas-pz-cel-bla/2462154/The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) of Abeona Therapeutics Inc.’s pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patient
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Can a New Bacteriocin Thwart Antibiotic Resistance?https://practicaldermatology.com/news/can-a-new-bacteriocin-thwart-antibiotic-resistance/2462150/A new bacteriocin in a very common skin bacterium may inhibit the growth of antibiotic-resistant bacteria, new research suggests. The research group for child and youth health at UiT The Arctic University of Norway has studied bacter
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh